Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus

Yoshihiro Kano, Masamitsu Konno, Koichi Kawamoto, Keisuke Tamari, Kazuhiko Hayashi, Takahito Fukusumi, Taroh Satoh, Shinji Tanaka, Kazuhiko Ogawa, Masaki Mori, Yuichiro Doki, Hideshi Ishii

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cancer stem cells (CSCs) have been identified in several tumor tissues. Since CSCs are resistant to cancer therapies, including chemotherapy and radiation therapy, and can even remain after therapies, tumor tissue often regrows and relapses. Thus, identification of CSCs and treatment targeting CSCs are required to treat tumor tissues. Reportedly, a fluorescent vector consisting of fluorescein ZsGreen fused to the carboxyl-terminal region of ornithine decarboxylase (cODC) was used to detect CSCs or therapy-resistant cancer cells in tumor tissues of the brain, pancreas and liver. Cells transfected with the fluorescent vector can express a fluorescein fused to cODC and become fluorescent only when the fusion protein is accumulated. In the present study, CSCs or therapy-resistant cancer cells were identified with the fluorescent vector in esophageal squamous cell carcinoma. The use of this fluorescent vector in drug screening enabled the detection of three drugs, AKT inhibitor XI, ERK inhibitor II and JAK inhibitor I, which target malignant CSCs.

Original languageEnglish
Pages (from-to)1133-1138
Number of pages6
JournalOncology reports
Volume31
Issue number3
DOIs
Publication statusPublished - Mar 1 2014

Fingerprint

Neoplastic Stem Cells
Drug Discovery
Esophagus
Squamous Cell Carcinoma
Cell- and Tissue-Based Therapy
Neoplasms
Ornithine Decarboxylase
Fluorescein
Preclinical Drug Evaluations
Brain Neoplasms
Pancreas
Radiotherapy
Recurrence
Drug Therapy
Liver
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kano, Y., Konno, M., Kawamoto, K., Tamari, K., Hayashi, K., Fukusumi, T., ... Ishii, H. (2014). Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. Oncology reports, 31(3), 1133-1138. https://doi.org/10.3892/or.2013.2952

Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. / Kano, Yoshihiro; Konno, Masamitsu; Kawamoto, Koichi; Tamari, Keisuke; Hayashi, Kazuhiko; Fukusumi, Takahito; Satoh, Taroh; Tanaka, Shinji; Ogawa, Kazuhiko; Mori, Masaki; Doki, Yuichiro; Ishii, Hideshi.

In: Oncology reports, Vol. 31, No. 3, 01.03.2014, p. 1133-1138.

Research output: Contribution to journalArticle

Kano, Y, Konno, M, Kawamoto, K, Tamari, K, Hayashi, K, Fukusumi, T, Satoh, T, Tanaka, S, Ogawa, K, Mori, M, Doki, Y & Ishii, H 2014, 'Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus', Oncology reports, vol. 31, no. 3, pp. 1133-1138. https://doi.org/10.3892/or.2013.2952
Kano, Yoshihiro ; Konno, Masamitsu ; Kawamoto, Koichi ; Tamari, Keisuke ; Hayashi, Kazuhiko ; Fukusumi, Takahito ; Satoh, Taroh ; Tanaka, Shinji ; Ogawa, Kazuhiko ; Mori, Masaki ; Doki, Yuichiro ; Ishii, Hideshi. / Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus. In: Oncology reports. 2014 ; Vol. 31, No. 3. pp. 1133-1138.
@article{9b409181113041bb880d6a390c47d82e,
title = "Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus",
abstract = "Cancer stem cells (CSCs) have been identified in several tumor tissues. Since CSCs are resistant to cancer therapies, including chemotherapy and radiation therapy, and can even remain after therapies, tumor tissue often regrows and relapses. Thus, identification of CSCs and treatment targeting CSCs are required to treat tumor tissues. Reportedly, a fluorescent vector consisting of fluorescein ZsGreen fused to the carboxyl-terminal region of ornithine decarboxylase (cODC) was used to detect CSCs or therapy-resistant cancer cells in tumor tissues of the brain, pancreas and liver. Cells transfected with the fluorescent vector can express a fluorescein fused to cODC and become fluorescent only when the fusion protein is accumulated. In the present study, CSCs or therapy-resistant cancer cells were identified with the fluorescent vector in esophageal squamous cell carcinoma. The use of this fluorescent vector in drug screening enabled the detection of three drugs, AKT inhibitor XI, ERK inhibitor II and JAK inhibitor I, which target malignant CSCs.",
author = "Yoshihiro Kano and Masamitsu Konno and Koichi Kawamoto and Keisuke Tamari and Kazuhiko Hayashi and Takahito Fukusumi and Taroh Satoh and Shinji Tanaka and Kazuhiko Ogawa and Masaki Mori and Yuichiro Doki and Hideshi Ishii",
year = "2014",
month = "3",
day = "1",
doi = "10.3892/or.2013.2952",
language = "English",
volume = "31",
pages = "1133--1138",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Novel drug discovery system for cancer stem cells in human squamous cell carcinoma of the esophagus

AU - Kano, Yoshihiro

AU - Konno, Masamitsu

AU - Kawamoto, Koichi

AU - Tamari, Keisuke

AU - Hayashi, Kazuhiko

AU - Fukusumi, Takahito

AU - Satoh, Taroh

AU - Tanaka, Shinji

AU - Ogawa, Kazuhiko

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Ishii, Hideshi

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Cancer stem cells (CSCs) have been identified in several tumor tissues. Since CSCs are resistant to cancer therapies, including chemotherapy and radiation therapy, and can even remain after therapies, tumor tissue often regrows and relapses. Thus, identification of CSCs and treatment targeting CSCs are required to treat tumor tissues. Reportedly, a fluorescent vector consisting of fluorescein ZsGreen fused to the carboxyl-terminal region of ornithine decarboxylase (cODC) was used to detect CSCs or therapy-resistant cancer cells in tumor tissues of the brain, pancreas and liver. Cells transfected with the fluorescent vector can express a fluorescein fused to cODC and become fluorescent only when the fusion protein is accumulated. In the present study, CSCs or therapy-resistant cancer cells were identified with the fluorescent vector in esophageal squamous cell carcinoma. The use of this fluorescent vector in drug screening enabled the detection of three drugs, AKT inhibitor XI, ERK inhibitor II and JAK inhibitor I, which target malignant CSCs.

AB - Cancer stem cells (CSCs) have been identified in several tumor tissues. Since CSCs are resistant to cancer therapies, including chemotherapy and radiation therapy, and can even remain after therapies, tumor tissue often regrows and relapses. Thus, identification of CSCs and treatment targeting CSCs are required to treat tumor tissues. Reportedly, a fluorescent vector consisting of fluorescein ZsGreen fused to the carboxyl-terminal region of ornithine decarboxylase (cODC) was used to detect CSCs or therapy-resistant cancer cells in tumor tissues of the brain, pancreas and liver. Cells transfected with the fluorescent vector can express a fluorescein fused to cODC and become fluorescent only when the fusion protein is accumulated. In the present study, CSCs or therapy-resistant cancer cells were identified with the fluorescent vector in esophageal squamous cell carcinoma. The use of this fluorescent vector in drug screening enabled the detection of three drugs, AKT inhibitor XI, ERK inhibitor II and JAK inhibitor I, which target malignant CSCs.

UR - http://www.scopus.com/inward/record.url?scp=84896694472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896694472&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2952

DO - 10.3892/or.2013.2952

M3 - Article

C2 - 24378718

AN - SCOPUS:84896694472

VL - 31

SP - 1133

EP - 1138

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 3

ER -